Published in J Bone Miner Res on October 01, 2008
The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab (2009) 1.52
Physiology of bone loss. Radiol Clin North Am (2010) 1.09
Testosterone and the male skeleton: a dual mode of action. J Osteoporos (2011) 0.81
Lasofoxifene: Evidence of its therapeutic value in osteoporosis. Core Evid (2010) 0.78
Interaction between bone and muscle in older persons with mobility limitations. Curr Pharm Des (2014) 0.77
Aromatase activity and bone loss in men. J Osteoporos (2011) 0.77
Gender Disparities in Osteoporosis. J Clin Med Res (2017) 0.75
Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res (2008) 2.44
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
Osteoporosis: now and the future. Lancet (2011) 5.81
Circulating osteoblast-lineage cells in humans. N Engl J Med (2005) 4.19
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03
Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res (2004) 4.02
Fat tissue, aging, and cellular senescence. Aging Cell (2010) 3.34
Mechanisms of anabolic therapies for osteoporosis. N Engl J Med (2007) 3.33
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom (2008) 2.87
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res (2008) 2.76
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract (2004) 2.69
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone (2008) 2.53
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Clinical review: Rare causes of hypercalcemia. J Clin Endocrinol Metab (2005) 2.38
Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab (2010) 2.33
For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int (2009) 2.32
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom (2013) 2.29
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res (2005) 2.15
The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab (2008) 2.12
Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. J Bone Miner Res (2007) 2.11
Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res (2008) 2.07
Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J Clin Endocrinol Metab (2006) 2.04
The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev (2005) 2.03
Age-dependence of femoral strength in white women and men. J Bone Miner Res (2010) 2.03
High-resolution peripheral quantitative computed tomography can assess microstructural and mechanical properties of human distal tibial bone. J Bone Miner Res (2010) 2.01
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
Structural determinants of vertebral fracture risk. J Bone Miner Res (2007) 1.97
Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 1.96
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol (2012) 1.94
Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab (2006) 1.91
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res (2014) 1.90
Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun (2005) 1.89
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Differences in bone microarchitecture between postmenopausal Chinese-American and white women. J Bone Miner Res (2011) 1.86
Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res (2014) 1.86
Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res (2008) 1.82
Application of high-resolution skeletal imaging to measurements of volumetric BMD and skeletal microarchitecture in Chinese-American and white women: explanation of a paradox. J Bone Miner Res (2009) 1.76
Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem (2003) 1.76
Bone structure at the distal radius during adolescent growth. J Bone Miner Res (2009) 1.74
The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology (2010) 1.74
Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab (2004) 1.71
Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J Bone Miner Res (2012) 1.63
Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2009) 1.59
Role of circulating osteogenic progenitor cells in calcific aortic stenosis. J Am Coll Cardiol (2012) 1.59
Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc (2009) 1.59
Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT. J Bone Miner Res (2006) 1.58
Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol (2008) 1.55
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab (2013) 1.51
Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab (2007) 1.51
Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine (2012) 1.50
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol (2005) 1.48
Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem (2003) 1.48
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res (2002) 1.46
Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res (2008) 1.46
Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res (2003) 1.42
Accelerated fracture healing with teriparatide. Arq Bras Endocrinol Metabol (2013) 1.41
The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab (2003) 1.41
Fracture risk following bilateral orchiectomy. J Urol (2003) 1.41
Remodeling and vascular spaces in bone. J Bone Miner Res (2007) 1.39
"Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab (2003) 1.39
Relationship of age to bone microstructure independent of areal bone mineral density. J Bone Miner Res (2012) 1.37
Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.35
Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res (2007) 1.35
Better skeletal microstructure confers greater mechanical advantages in Chinese-American women versus white women. J Bone Miner Res (2011) 1.34
Perspectives on glucocorticoid-induced osteoporosis. Bone (2004) 1.34
Relation of vertebral deformities to bone density, structure, and strength. J Bone Miner Res (2010) 1.32
Increasing options for the treatment of osteoporosis. N Engl J Med (2009) 1.32
Nonoxidative free fatty acid disposal is greater in young women than men. J Clin Endocrinol Metab (2010) 1.31
PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res (2011) 1.30
Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab (2006) 1.30
Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab (2003) 1.30
Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology (2003) 1.28
Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res (2003) 1.28
Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int (2005) 1.27
Characterization of circulating osteoblast lineage cells in humans. Bone (2007) 1.27
Robust QCT/FEA models of proximal femur stiffness and fracture load during a sideways fall on the hip. Ann Biomed Eng (2010) 1.26
A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab (2008) 1.26
Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab (2012) 1.26
Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab (2012) 1.24
Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements. FASEB J (2008) 1.24
Population-based analysis of the relationship of whole bone strength indices and fall-related loads to age- and sex-specific patterns of hip and wrist fractures. J Bone Miner Res (2005) 1.24
Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res (2005) 1.23
Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol (2011) 1.23
Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. J Bone Miner Res (2014) 1.21
The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord (2006) 1.21
High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J Bone Miner Res (2007) 1.21
Parathyroid carcinoma. J Bone Miner Res (2008) 1.20
Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care (2007) 1.20
Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone (2011) 1.19